Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 398441 - 398460 out of 563611 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Norway | (L01FD02) pertuzumab | Perjeta 420 mg | 1 x 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 420 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | RocheRegistrationGmbH |
| Norway | (L01FD03) trastuzumab emtansine | Kadcyla 100 mg | 100 mg, Hetteglass, Pulver til konsentrat til infusjonsvæske, oppløsning, 100 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | RocheRegistrationGmbH |
| Norway | (L01FD03) trastuzumab emtansine | Kadcyla 160 mg | 160 mg, Hetteglass, Pulver til konsentrat til infusjonsvæske, oppløsning, 160 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | RocheRegistrationGmbH |
| Norway | (L01FD04) trastuzumab deruxtecan | Enhertu 100 mg | 100 mg, Hetteglass, Pulver til konsentrat til infusjonsvæske, oppløsning, 100 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | DaiichiSankyoEuropeGmbH |
| Norway | (L01FF01) nivolumab | Opdivo 10 mg/ml | 1 x 10 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 10 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbPharmaEEIG |
| Norway | (L01FF01) nivolumab | Opdivo 10 mg/ml | 1 x 4 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 10 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbPharmaEEIG |
| Norway | (L01FF01) nivolumab | Opdivo 10 mg/ml | 1 x 24 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 10 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbPharmaEEIG |
| Norway | (L01FF01) nivolumab | Opdivo 10 mg/ml | 1 x 12 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 10 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbPharmaEEIG |
| Norway | (L01FF02) pembrolizumab | Keytruda 25 mg/ml | 4 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 25 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms | MerckSharp&DohmeB.V.(1) |
| Norway | (L01FF03) durvalumab | Imfinzi 50 mg/ml | 2.4 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 50 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaAB(2) |
| Norway | (L01FF03) durvalumab | Imfinzi 50 mg/ml | 10 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 50 mg/ml , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaAB(2) |
| Norway | (L01FF05) atezolizumab | Tecentriq 1 200 mg | 1 x 20 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 1 200 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | AbacusMedicineA/S |
| Norway | (L01FF05) atezolizumab | Tecentriq 1 200 mg | 20 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 1 200 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | OrifarmAS |
| Norway | (L01FF05) atezolizumab | Tecentriq 1 200 mg | 20 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 1 200 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF05) atezolizumab | Tecentriq 840 mg | 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 840 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF05) atezolizumab | Tecentriq 840 mg | 1 x 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 840 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | AbacusMedicineA/S |
| Norway | (L01FF05) atezolizumab | Tecentriq 840 mg | 14 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 840 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | OrifarmAS |
| Norway | (L01FF05) atezolizumab | Tecentriq 1 875 mg | 15 ml, Hetteglass, Injeksjonsvæske, oppløsning, 1 875 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma | RocheRegistrationGmbH |
| Norway | (L01FF06) cemiplimab | Libtayo 350 mg | 1 x 7 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 350 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Squamous Cell | RegeneronIrelandDesignatedActivityCompany(DAC) |
| Norway | (L01FF06) cemiplimab | Libtayo 350 mg | 7 ml, Hetteglass, Konsentrat til infusjonsvæske, oppløsning, 350 mg , Hetteglass | Retail price with vat |
$0-0 |
$0-0 |
Carcinoma, Squamous Cell | OrifarmAS |
Pages
